(Q36880257)

16 August 2017

0 references

1 reference

title

Risks and benefits associated with novel phase 1 oncology trial designs (English)

1 reference

16 August 2017

phase I clinical trial

0 references

6

Ezekiel J Emanuel

1 reference

16 August 2017

7

Cary P Gross

1 reference

16 August 2017

Shlomo A Koyfman

1

1 reference

16 August 2017

Manish Agrawal

2

1 reference

16 August 2017

Elizabeth Garrett-Mayer

3

1 reference

16 August 2017

Benjamin Krohmal

4

1 reference

16 August 2017

Elizabeth Wolf

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

16 August 2017

1 reference

16 August 2017

110

1 reference

16 August 2017

5

1 reference

16 August 2017

1115-1124

1 reference

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.

16 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

Phase I trial design: are new methodologies being put into practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

Phase I cancer trials. A collusion of misunderstanding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

Learning from our patients: one participant's impact on clinical trial research and informed consent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Ethics of phase 1 oncology studies: reexamining the arguments and data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

A phase I trial on the ethics of phase I trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Risks and benefits of phase 1 oncology trials, revisited

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Phase 1 clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Study of cohort-specific consent and patient control in phase I cancer trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Pushing the envelope: informed consent in phase I trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Descriptions of benefits and risks in consent forms for phase 1 oncology trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Quality of informed consent in cancer clinical trials: a cross-sectional survey

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Informed consent for investigational chemotherapy: patients' and physicians' perceptions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Choice of starting dose and escalation for phase I studies of antitumor agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Phase I clinical trial design in cancer drug development.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Measures of response: RECIST, WHO, and new alternatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Dose-finding based on efficacy-toxicity trade-offs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22878

7 January 2021

Identifiers

DOI

10.1002/CNCR.22878

1 reference

16 August 2017

1 reference